|
Jan 9
|
NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
|
|
Dec 27
|
NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
|
|
Dec 6
|
We're A Little Worried About NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Rate
|
|
Dec 5
|
NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
|
|
Dec 4
|
NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
|
|
Nov 28
|
NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
|
|
Oct 4
|
NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
|
|
Oct 3
|
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
|
|
Oct 2
|
NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results
|
|
Jul 17
|
NeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
|